Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
- Published: Aug 2019
- Pages: 157
- SKU: IRTNTR31940
Enjoy complimentary customisation on priority with our Enterprise License!
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
The chronic myelogenous leukemia therapeutics market size will grow by USD 1.74 billion during 2019-2023. This market report provides a detailed analysis of the market by product (targeted therapy, chemotherapy, and immunotherapy) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on many market vendors, including Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.
Key Insights on Chronic Myelogenous Leukemia Therapeutics Market – Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of Chronic Myelogenous Leukemia Therapeutics Market
Industry Overview
The CML therapeutics market has witnessed a number of strategic alliances over recent years. Market vendors are focusing on collaborations to expand their distribution networks and reduce costs associated with the R&D of CML therapeutics. Collaborations among vendors are influencing market growth by increasing patient adherence by reducing the cost burden. For instance, the BMS recently collaborated with The MAX Foundation to provide free drugs to patients who are unable to access the treatment. The strategic alliances between vendors have also increased the development of diagnostic kits and testing services, which have resulted in the early diagnosis of the disease and increased adoption for the treatment. Effective alliances among companies will significantly fuel the growth of the CML therapeutics market size during 2019-2023.
Crucial chronic myelogenous leukemia therapeutics market trends such as the development of diagnostic tests and predictive markers will also influence market growth. The high unmet need is encouraging companies to research diagnostic testing methods that help in the early detection of CML. These developments include diagnostic kits in oncology to effectively monitor the molecular response of the indication at an early stage. Vendors are also introducing predictive biomarkers for CML for the intrinsic sensitivity of TKI drugs. For instance, HMGCLL1 is a predictive biomarker in CML for deep molecular response to imatinib therapy.
Similarly, microRNAs are used as biomarkers to study the progression of CML and the resistance to TKI drugs. These developments are expected to enhance the effectiveness of CML therapy drugs. As a result of these factors, the myelogenous leukemia therapeutics market will register a CAGR of nearly 6% during the forecast period.
Top Companies in Chronic Myelogenous Leukemia Therapeutics Market
The global market is fragmented. To help clients improve their market positions, this chronic myelogenous leukemia therapeutics market forecast report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. This chronic myelogenous leukemia therapeutics market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading chronic myelogenous leukemia therapeutics companies, including:
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Mylan NV
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
Market Segmentation
Chronic Myelogenous Leukemia Market by Product
- Targeted therapy
- Chemotherapy
- Immunotherapy
The targeted therapy segment held the largest market share in 2018. It will account for the highest chronic myelogenous leukemia therapeutics market share over the forecast period as well. The market is witnessing an increase in the number of approved TKI drugs for the treatment of chronic phase CML. The increasing number of approvals for orphan drug destinations is also fueling the growth of the segment. This report provides an accurate prediction of the contribution of all the segments to the growth of the chronic myelogenous leukemia therapeutics market size.
Chronic Myelogenous Leukemia Therapeutics Market by Geography
- Asia
- Europe
- North America
- ROW
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest share of the chronic myelogenous leukemia therapeutics market throughout the forecast period. Vendors operating in the region are providing patient-assistance programs, such as co-pay assistance and free trial programs to reduce patients’ burden. These patient-assistance programs are also inclusive of reimbursement support, financial co-payment assistance, medication adherence, and supportive care. Such initiatives by vendors are fueling the chronic myelogenous leukemia therapeutics market growth in North America.
Major Highlights of the Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the chronic myelogenous leukemia therapeutics market size during the next five years
- Precise estimation of the global chronic myelogenous leukemia therapeutics market size and its contribution to the parent market
- Accurate chronic myelogenous leukemia therapeutics market forecast on upcoming trends and changes in consumer behavior
- The growth of the chronic myelogenous leukemia therapeutics industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details of factors that will challenge the growth of chronic myelogenous leukemia therapeutics companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Targeted therapy - Market size and forecast 2018-2023
- Chemotherapy - Market size and forecast 2018-2023
- Immunotherapy - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 10: MARKET TRENDS
- Emergence of pipeline molecules
- Development of diagnostic tests and predictive markers
- Increasing research in regenerative medicines
PART 11: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 12: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Mylan NV
- Novartis AG
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
PART 13: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 14: EXPLORE TECHNAVIO
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Key Questions Answered
- What are the key global market and the regional market share?
- What are the revenue-generating key market segments?
- What are the key factors driving and challenging this market’s growth?
- Who are the key market vendors and their growth strategies?
- What are the latest trends influencing the growth of this market?
- What are the variables influencing the market growth in the primary regions?
- What are the factors influencing the growth of the parent market?
Why should you prefer Technavio's market insights report?
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Single:
One user only.
Quick & easy download optionEnterprise:
Unlimited user access (Within your organization)
Complimentary Customization Included
2500 USD
Get the report (PDF) sent to your email within minutes.
Subscribe & Save
Get lifetime access to our
Technavio Insights
Did you know?
Did you know?
Did you know?
Customized Report as per your Business Needs
- Our analysts will work directly with you and understand your needs
- Get data on specified regions or segments, competitor and Vendors
- Data will be formatted and presented as per your requirements
- We offer $1000 worth of FREE customization at the time of purchase
Let us help you make report more suited to your requirements.
- Get a competitive breakdown as per your niche industry
- Customize the data with various metrics that meet your business prerequisite
- Understand Revenue Sources, Customers and many more
- Details on Market Share
- These customizations are done in a short amount of time by our analysts and industry experts
